GTBP - GT Biopharma adds new trial site for early-stage acute myeloid leukemia study

GT Biopharma (GTBP) announces the addition of the University of Wisconsin's Madison Carbone Cancer Center as a new clinical trial site for its ongoing GTB-3550 TriKE multicenter Phase I/II trial, testing the treatment in certain patients with acute myeloid leukemia ((AML)).GTB-3550 TriKE is being evaluated in patients age 18 and older with CD33+ malignancies (primary induction failure or relapsed acute myeloid leukemia ((AML)) with failure of one reinduction attempt, or high-risk myelodysplastic syndromes ((MDS)) progressed on two lines of therapy).The primary endpoint of the study is to identify the maximum tolerated dose and safety of GTB-3550.Shares of the company were trading down nearly 10% premarket.

For further details see:

GT Biopharma adds new trial site for early-stage acute myeloid leukemia study